Bushi Wang

IO Biotech ApS - Copenhagen / Denmark

Medical and Health Sciences / Biostatistics

AD Scientific Index ID: 4985121

Registration, Add Profile,
Premium Membership

Print Your Certificate

Bushi Wang's MOST POPULAR ARTICLES

1-) Idarucizumab for dabigatran reversal CV Pollack Jr, PA Reilly, J Eikelboom, S Glund, P Verhamme, ... New England Journal of Medicine 373 (6), 511-520, 2015 19442015

2-) Idarucizumab for Dabigatran Reversal—Full Cohort Analysis CV Pollack Jr, PA Reilly, J van Ryn, JW Eikelboom, S Glund, ... New England Journal of Medicine 377 (5), 431-441, 2017 10322017

3-) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial JC Soria, E Felip, M Cobo, S Lu, K Syrigos, KH Lee, E Göker, ... The Lancet Oncology 16 (8), 897-907, 2015 4532015

4-) Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor–resistant EGFR-mutant lung cancer with and without T790M mutationsYY Janjigian, EF Smit, HJM Groen, L Horn, S Gettinger, DR Camidge, ...Cancer discovery 4 (9), 1036-1045, 20144352014

5-) Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatranCV Pollack Jr, PA Reilly, R Bernstein, R Dubiel, J Eikelboom, S Glund, ...Thrombosis and haemostasis 114 (07), 198-205, 20152002015

ARTICLES

Add your articles